Medicare Part D
Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs
Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
Key contributors to the total: Sovaldi, Harvoni and Olysio
President Barack Obama states in budget proposal that government should negotiate drug pricing; J&J's rare cancer drug's review is expedited; inhalable insulin hits pharmacy shelves.
The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.
The agency's move to limit the formulary for certain drug classes is dead.
The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.
HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.
The drug maker can now add five new doses to its generic Opana ER offerings.
The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
Congressional Republicans are trumpeting a cache of emails that give a glimpse into how the White House's deal with the pharma industry on healthcare reform came together. There's not much 'there' there, but there are some titillating glimpses into the legislative sausage factory.
The National Coalition on Health Care took aim at co-pay cards and coupons with a report suggesting that they might push 2 million US seniors to opt for more expensive branded drugs over generics.
President Obama's proposed 2013 budget would mandate an estimated $156 billion in new rebates to low-income seniors through Medicare over the next decade - discounts that would come out of the pockets of drug companies and could cost tens of thousands of jobs, according to PhRMA.
Armed with AARP and Kaiser Family research, members of the Senate Special Committee on Aging asked panelists why brand drug prices in the US continue to increase, while other countries pay half as much for the same products.
PhRMA has committed to finding $80 billion in savings on drugs sold in the US over 10 years, including selling drugs at half-price to seniors in the Medicare Part D "donut hole" coverage gap.
Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.
- Curious if you're a finalist in the MM&M Awards? Find out now
- Vertex's Orkambi nabs FDA approval but may face payer backlash
- Fit4D expands diabetes program with Healthfirst
- Steady Leadership, Focus on Infrastructure Expected from the FDA's "Acting" Head
- Five things for pharma marketers to know: Monday, July 6
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.